JP2019537582A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019537582A5 JP2019537582A5 JP2019522710A JP2019522710A JP2019537582A5 JP 2019537582 A5 JP2019537582 A5 JP 2019537582A5 JP 2019522710 A JP2019522710 A JP 2019522710A JP 2019522710 A JP2019522710 A JP 2019522710A JP 2019537582 A5 JP2019537582 A5 JP 2019537582A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- subject
- hearing loss
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 34
- 206010011878 Deafness Diseases 0.000 claims 11
- 230000001684 chronic effect Effects 0.000 claims 11
- 230000010370 hearing loss Effects 0.000 claims 11
- 231100000888 hearing loss Toxicity 0.000 claims 11
- 208000016354 hearing loss disease Diseases 0.000 claims 11
- SRHWORQGHZESJE-UHFFFAOYSA-N N-[1-(4,6-disulfonylcyclohex-2-en-1-yl)-2,2-dimethylpropylidene]hydroxylamine Chemical compound CC(C)(C)C(=NO)C1C=CC(CC1=S(=O)=O)=S(=O)=O SRHWORQGHZESJE-UHFFFAOYSA-N 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 208000015181 infectious disease Diseases 0.000 claims 3
- 206010063602 Exposure to noise Diseases 0.000 claims 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims 2
- 229960004308 acetylcysteine Drugs 0.000 claims 2
- 210000003030 auditory receptor cell Anatomy 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 230000002708 enhancing effect Effects 0.000 claims 2
- 238000004880 explosion Methods 0.000 claims 2
- 231100000573 exposure to toxins Toxicity 0.000 claims 2
- 210000004307 hair cells vestibular Anatomy 0.000 claims 2
- 230000014511 neuron projection development Effects 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 2
- 230000000946 synaptic effect Effects 0.000 claims 2
- 230000001720 vestibular Effects 0.000 claims 2
- JKRODHBGNBKZLE-YUMQZZPRSA-N (2s)-2-amino-5-[[(2r)-1-[(2-ethoxy-2-oxoethyl)amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CCOC(=O)CNC(=O)[C@H](CS)NC(=O)CC[C@H](N)C(O)=O JKRODHBGNBKZLE-YUMQZZPRSA-N 0.000 claims 1
- FFEARJCKVFRZRR-SCSAIBSYSA-N D-methionine Chemical compound CSCC[C@@H](N)C(O)=O FFEARJCKVFRZRR-SCSAIBSYSA-N 0.000 claims 1
- 229930182818 D-methionine Natural products 0.000 claims 1
- DYEFUKCXAQOFHX-UHFFFAOYSA-N Ebselen Chemical compound [se]1C2=CC=CC=C2C(=O)N1C1=CC=CC=C1 DYEFUKCXAQOFHX-UHFFFAOYSA-N 0.000 claims 1
- 206010020559 Hyperacusis Diseases 0.000 claims 1
- 208000027530 Meniere disease Diseases 0.000 claims 1
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 claims 1
- 206010036626 Presbyacusis Diseases 0.000 claims 1
- 108700024319 S-ethyl glutathione Proteins 0.000 claims 1
- 208000009205 Tinnitus Diseases 0.000 claims 1
- 238000009825 accumulation Methods 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229950010033 ebselen Drugs 0.000 claims 1
- 239000002360 explosive Substances 0.000 claims 1
- 210000000067 inner hair cell Anatomy 0.000 claims 1
- 238000007913 intrathecal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 230000001537 neural effect Effects 0.000 claims 1
- 210000002241 neurite Anatomy 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 210000002985 organ of corti Anatomy 0.000 claims 1
- 208000009800 presbycusis Diseases 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 230000008929 regeneration Effects 0.000 claims 1
- 238000011069 regeneration method Methods 0.000 claims 1
- 210000000225 synapse Anatomy 0.000 claims 1
- 230000007470 synaptic degeneration Effects 0.000 claims 1
- 102000013498 tau Proteins Human genes 0.000 claims 1
- 108010026424 tau Proteins Proteins 0.000 claims 1
- 231100000886 tinnitus Toxicity 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 108700012359 toxins Proteins 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662415101P | 2016-10-31 | 2016-10-31 | |
| US62/415,101 | 2016-10-31 | ||
| US201762488740P | 2017-04-22 | 2017-04-22 | |
| US62/488,740 | 2017-04-22 | ||
| US201762510596P | 2017-05-24 | 2017-05-24 | |
| US62/510,596 | 2017-05-24 | ||
| US201762550345P | 2017-08-25 | 2017-08-25 | |
| US62/550,345 | 2017-08-25 | ||
| PCT/US2017/058834 WO2018081614A1 (en) | 2016-10-31 | 2017-10-27 | Methods for enhancing synaptogenesis and neuritogenesis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019537582A JP2019537582A (ja) | 2019-12-26 |
| JP2019537582A5 true JP2019537582A5 (https=) | 2020-12-03 |
Family
ID=62020809
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019522710A Pending JP2019537582A (ja) | 2016-10-31 | 2017-10-27 | シナプス形成および神経突起形成を増強するための方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US10576125B2 (https=) |
| EP (1) | EP3532042A4 (https=) |
| JP (1) | JP2019537582A (https=) |
| CN (1) | CN110248650A (https=) |
| WO (1) | WO2018081614A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021522282A (ja) | 2018-04-27 | 2021-08-30 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ | リソソーム蓄積障害の治療 |
| US12076330B2 (en) | 2018-04-27 | 2024-09-03 | The Regents Of The University Of California | Inhibition of lipofuscin aggregation by molecular tweezers |
| EP3787750A1 (en) * | 2018-05-03 | 2021-03-10 | Hough Ear Institute | Methods for reducing accumulated pathologic tau protein |
| US12121501B2 (en) | 2018-09-12 | 2024-10-22 | Hough Ear Institute | Methods for treating hearing loss incident to cochlear implant surgery |
| US20220153780A1 (en) * | 2019-03-26 | 2022-05-19 | Tonix Pharma Holdings Limited | Salt forms of s-(n, n-diethylcarbamoyl)glutathione |
| WO2020243478A1 (en) * | 2019-05-29 | 2020-12-03 | Massachusetts Eye And Ear Infirmary | Fibroblast growth factor 2 (fgf2) for treatment of human sensorineural hearing loss |
| CN112939823A (zh) * | 2019-12-10 | 2021-06-11 | 中国石油天然气股份有限公司 | 泥页岩抑制剂制备方法及抑制剂的应用 |
| WO2025245095A1 (en) * | 2024-05-20 | 2025-11-27 | Therapeutic Vision, Inc. | Method of preventing blast-induced loss of cochlear and vestibular hair cells and auditory spiral ganglion neurons |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5488145A (en) * | 1993-12-23 | 1996-01-30 | Oklahoma Medical Research Foundation | 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps |
| US6064064A (en) * | 1996-03-01 | 2000-05-16 | Fire Sentry Corporation | Fire detector |
| EP1126855B1 (en) | 1998-09-25 | 2007-05-09 | Cephalon, Inc. | Use of fused pyrrolocarbazoles for preventing/treating damage to sensory hair cells and cochlear neurons |
| EP2278999B1 (en) | 2008-04-21 | 2025-01-29 | Dompé farmaceutici S.p.A. | Auris formulations for treating otic diseases and conditions |
| TR201911199T4 (tr) | 2009-03-27 | 2019-08-21 | Moleac Pte Ltd | Hücre büyümesini arttırmak için tedavi. |
| EP2470015B1 (en) * | 2009-08-24 | 2016-01-13 | Hough Ear Institute | Nitrone compounds for treating sensorineural hearing loss |
| ES2893825T3 (es) | 2011-02-04 | 2022-02-10 | Hough Ear Inst | Métodos de tratamiento de lesiones cerebrales |
| EP2872128B1 (en) * | 2012-07-16 | 2020-02-19 | Cornell University | Nicotinamide riboside to treat hearing loss |
| US20150209367A1 (en) | 2012-09-07 | 2015-07-30 | Massachusetts Eye & Ear Infirmary | Treating Hearing Loss |
| DK3004080T3 (da) | 2013-06-04 | 2019-01-02 | Acturum Real Estate Ab | Triazolforbindelser og deres anvendelse som gamma-sekretase-modulatorer |
| US20180256756A1 (en) * | 2015-09-18 | 2018-09-13 | Oklahoma Medical Research Foundation | Method of transporting an agent across blood-brain, blood-cochlear or blood-cerebrospinal fluid barrier |
-
2017
- 2017-10-27 US US15/796,522 patent/US10576125B2/en active Active
- 2017-10-27 WO PCT/US2017/058834 patent/WO2018081614A1/en not_active Ceased
- 2017-10-27 JP JP2019522710A patent/JP2019537582A/ja active Pending
- 2017-10-27 EP EP17866191.4A patent/EP3532042A4/en active Pending
- 2017-10-27 CN CN201780078374.7A patent/CN110248650A/zh active Pending
-
2020
- 2020-01-30 US US16/777,750 patent/US20200164021A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019537582A5 (https=) | ||
| US12336974B2 (en) | Methods and compositions for preventing and treating auditory dysfunctions | |
| JP2007513079A5 (https=) | ||
| JP2013521231A5 (https=) | ||
| JP2021512920A5 (https=) | ||
| JP2019511496A5 (https=) | ||
| CN117919232B (zh) | 吲哚丙酸在治疗肝硬化以及免疫性肝损伤的应用 | |
| JP2019537582A (ja) | シナプス形成および神経突起形成を増強するための方法 | |
| JP2019513814A5 (https=) | ||
| JP2021527053A5 (https=) | ||
| JP2006524243A5 (https=) | ||
| JP2018505218A5 (https=) | ||
| JP2021523126A5 (https=) | ||
| US20210137861A1 (en) | Methods for reducing accumulated pathologic tau protein | |
| CN118787626A (zh) | 一种d-丝氨酸化合物在制备神经调节剂和治疗脑功能障碍药物中的应用 | |
| CN104435465B (zh) | 一种治疗帕金森病的中药组合物 | |
| US20220401420A1 (en) | Combination therapy having antioxydant properties | |
| WO2023079954A1 (ja) | 内耳性難聴の抑制又は予防のためのエルゴチオネインを含む組成物 | |
| RU2640133C1 (ru) | Применение пептида thr-lys-pro-arg-pro-gly-pro (селанк) для профилактики и лечения токсического гепатита | |
| JP2010540661A5 (https=) | ||
| AU2020376223B2 (en) | Combination therapy having antioxydant properties | |
| US20240150408A1 (en) | Methods and systems for targeting autoimmune and inflammatory pathways using nanoligomers | |
| TW202615083A (zh) | 環肽類似物及其製備方法和用途 | |
| JP2019513780A5 (https=) | ||
| WO2024215967A2 (en) | Compounds for treating rett syndrome and other disorders |